copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
South Africas Biovac in new oral cholera vaccine deal South Africa's Biovac Institute has signed a licensing and technology transfer deal with the International Vaccine Institute (IVI) to develop and make oral cholera vaccine for African and global
Ceva Biovac Who are we? Biovac Regulatory constraints and medical practices vary from country to country Consequently, the information provided on the site in which you enter may not be suitable for use in your country Who are we? The development of a vaccine solution: 6 to 10 weeks from detection to delivery Tel: +33 (0) 2 41 48 30 30 Fax: +33 (0) 2 41 48 34 94
Biovac signs deal with IVI to develop and manufacture oral cholera . . . It will allow Biovac to expand its capabilities from filling and packaging of vaccine vials to end-to-end vaccine product development and drug substance manufacture Biovac CEO, Dr Morena Makhoana, says the COVID-19 pandemic exposed Africa’s lack of local production capacity
BioVac Inc. BioVac supplies products in the field of Life Science, Biological Research and Vacuum applications
Biovacs Drive for Innovation: Partnering with IQVIA to Advance . . . The adoption of IQVIA's technology not only streamlined Biovac's workflow but also set new standards in healthcare technology, aligning with global practices This strategic collaboration marks a pivotal step in Biovac's evolution, enhancing its capabilities in vaccine supply and public health outcomes, and laying the groundwork for future